ArticleJournal of advanced research2026
Risperidone induces osteoporosis and neuropsychiatric treatment resistance via SMPD1-lysosome-mediated ferroptosis: dual rescue by active vitamin D analog ED-71.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cell Type-Specific Ferroptosis Regulatory Networks in the Bone Microenvironment: Implications for the Pathogenesis and Treatment of Osteoporosis.Traffic (Copenhagen, Denmark) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRisperidone (RIS), a second-generation antipsychotic for schizophrenia (SZ), is linked to osteoporosis and suboptimal symptom resolution. The shared cellular mechanisms underlying these cross-tissue toxicities (bone and hippocampus) remain undefined, hindering therapeutic advancement.
objectivesTo determine if RIS induces toxicity in osteoblasts and hippocampal GABAergic neurons via the acid sphingomyelinase (SMPD1)-lysosome axis, and to evaluate the therapeutic potential of eldecalcitol (ED-71), an active vitamin D analog, in mitigating these effects.
methodsDizocilpine-induced SZ mice were used to evaluate bone loss and psychiatric symptoms. Primary osteoblasts induced from bone marrow mesenchymal stem cells (BMSCs) and MC3T3-E1 osteoblasts, as well as primary hippocampal neurons and HT22 hippocampal neurons, were treated with RIS to evaluate ferroptosis, lysosomal dysfunction, and SMPD1 activity. Key techniques included micro-CT, histomorphometric staining, behavioral tests, enzyme-linked immunosorbent assay, RNA sequencing, targeted lipidomics analysis, molecular dynamics simulations, and isothermal titration calorimetry assays. Virtual drug screening was used to identify potential RIS-SMPD1 interaction antagonists, with the identified candidate ED-71 further validated thereafter.
resultsRIS targeted lysosomes, causing dysfunction and membrane permeabilization, which drove ferroptosis in osteoblasts and hippocampal GABAergic neurons. Mechanistically, RIS bound to SMPD1 at ARG294, inhibiting its activity and triggering lysosomal phospholipid accumulation and ferroptosis. ED-71 disrupted RIS-SMPD1 interactions, restored lysosomal integrity, mitigated hyperprolactinemia/sympathetic overactivation, and synergized with RIS to enhance antipsychotic efficacy and prevent osteoporosis in SZ models.
conclusionThis study identifies SMPD1 activation as a therapeutic target to counteract RIS-induced ferroptosis in bone and hippocampus. The dual-action mechanism of ED-71 provides a novel strategy for SZ intervention, simultaneously addressing psychiatric symptoms and osteoporotic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.